Laboratory of Microbiology Signals and Microenvironment, University of Rouen, 76821 Mont Saint Aignan, France.
Institute of Enzymology, Research Centre for Natural Sciences, ELKH 1117 Budapest, Hungary.
Cells. 2021 Jul 19;10(7):1818. doi: 10.3390/cells10071818.
A novel coronavirus discovered in 2019 is a new strain of the family (CoVs) that had not been previously identified in humans. It is known as SARS-CoV-2 for , whilst COVID-19 is the name of the disease associated with the virus. SARS-CoV-2 emerged over one year ago and still haunts the human community throughout the world, causing both healthcare and socioeconomic problems. SARS-CoV-2 is spreading with many uncertainties about treatment and prevention: the data available are limited and there are few randomized controlled trial data on the efficacy of antiviral or immunomodulatory agents. SARS-CoV-2 and its mutants are considered as unique within the family insofar as they spread rapidly and can have severe effects on health. Although the scientific world has been succeeding in developing vaccines and medicines to combat COVID-19, the appearance and the spread of new, more aggressive mutants are posing extra problems for treatment. Nevertheless, our understanding of pandemics is increasing significantly due to this outbreak and is leading to the development of many different pharmacological, immunological and other treatments. This Review focuses on a subset of COVID-19 research, primarily the cytoskeleton-related physiological and pathological processes in which coronaviruses such as SARS-CoV-2 are intimately involved. The discovery of the exact mechanisms of the subversion of host cells by SARS-CoV-2 is critical to the validation of specific drug targets and effective treatments.
一种于 2019 年发现的新型冠状病毒属于冠状病毒科(CoVs),此前尚未在人类中发现。它被称为 SARS-CoV-2,而与该病毒相关的疾病则称为 COVID-19。SARS-CoV-2 出现于一年多前,至今仍在全球范围内困扰着人类社会,引发了医疗保健和社会经济问题。SARS-CoV-2 传播迅速,有关治疗和预防措施的许多信息尚不确定:现有数据有限,关于抗病毒或免疫调节剂疗效的随机对照试验数据也很少。SARS-CoV-2 及其突变体被认为在冠状病毒科中是独特的,因为它们传播迅速,可能对健康造成严重影响。尽管科学界已经成功开发出针对 COVID-19 的疫苗和药物,但新的、更具攻击性的突变体的出现和传播给治疗带来了额外的问题。然而,由于此次疫情,我们对大流行的认识正在显著提高,并促使开发出许多不同的药理学、免疫学和其他治疗方法。这篇综述主要关注 COVID-19 研究的一个子集,即与 SARS-CoV-2 等冠状病毒密切相关的细胞骨架相关生理和病理过程。发现 SARS-CoV-2 颠覆宿主细胞的确切机制对于验证特定的药物靶点和有效的治疗方法至关重要。